Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase NA 23Phase 3 14Phase 1 6Phase 2/3 3Phase EARLY_PHASE1 2Phase 1/2 2Phase 4 1

Status

Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 11Breast 3Thoracic 1Gynecologic 1

Conditions

Breast Neoplasms 3Inflammatory Breast Neoplasms 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Neoadjuvant Therapy × Breast × Clear all
NCT01781338 2025-02-27

ADAPT

West German Study Group

Phase 2/3 Completed
4,936 enrolled
Breast

Breast Neoplasms

NCT06769919 2025-01-10

A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer

Xijing Hospital

Phase 2/3 Not yet recruiting
340 enrolled
Breast

Breast Neoplasms

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡